Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL5-6.2
- Development stage
- Preclinical
- Lead developer
- Bactolife
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
BL5-6.2 is an orally stable, heterodivalent single-domain antibody (VHH) binding protein developed by Bactolife. It is designed to target and neutralize Clostridioides difficile toxin B (TcdB) in the gastrointestinal tract. By binding to the glycosyltransferase domain (GTD) of TcdB, BL5-6.2 prevents toxin-mediated cytotoxicity, preserves epithelial barrier integrity, and reduces mucosal inflammation without disrupting the gut microbiota. Engineered for high stability under gastric acidity, pepsin, secondary bile acids, and thermal processing, BL5-6.2 is being developed as a food-grade functional ingredient or dietary supplement to support gut resilience and prevent Clostridioides difficile infection (CDI) in vulnerable populations.
- Other names
- anti-TcdB dimeric VHH binding proteinheterodivalent VHH construct BL5-6.2
02
Targets
TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on BL5-6.2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL5-6.2.